Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: A pilot study

Journal of Viral Hepatitis

Volumn 20, Issue SUPPL.1, 2013, Pages 52-57

  Huang, Z ^a,b   Zhao, Z ^a,b   Zheng, Y ^a,b   Peng, L ^a,b   Lin, C ^a,b   Deng, H ^a,b   Gao, Z ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

chronic hepatitis B; sequential use of telbivudine after pegylated interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS B; HUMAN; MALE; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THYMIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874593062     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12064     Document Type: Article

References (17)

1. Lok AS, McMahon BJ,. AASLD practice guidelines: chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-662.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis. B J Hepatol 2009; 50 (2): 227-242.
3. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008; 2 (3): 263-283.
4. Perrillo R,. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49 (5 Suppl): S103-111.
5. Negro F,. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol 2010; 24 (2): 183-192.
6. Gish RG, Lau DT, Schmid P, Perrillo R,. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102 (12): 2718-2723. (Pubitemid 350179320)
7. Shi TD, Zhang JM, Wang XF, et al,. Effects of antiviral therapy with telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med 2012; 12 (2): 105-113.
8. Ma SW, Huang X, Li YY, et al,. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012; 56 (4): 775-781.
9. Pan X, Yao W, Fu J, Liu M, Li L, Gao X,. Telbivudine improves the function of myeloid dendritic cells in patients with chronic hepatitis B. Acta Virol 2012; 56 (1): 31-38.
10. Lv G, Ying L, Ma WJ, et al,. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment. Virol J 2010; 7: 207.
11. Zheng Y, Huang Z, Chen X, et al,. Effects of telbivudine treatment on the circulating CD4â T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm 2012; 2012: 789859. Epub 2012 Apr 11.
12. Lai CL, Gane E, Liaw YF, et al,. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357 (25): 2576-2588. (Pubitemid 350294224)
13. Xue R, Chang JB, Wang JE,. Preliminary clinical study of efficacy on re-treatment for interferon suboptimal CHB patients. Zhonghua Ganzangbing Zazhi 2009; 17: 549-550 (in Chinese).
14. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-2695. (Pubitemid 41007823)
15. Lau GK, Piratvisuth T, Luo KX, et al,. Durability of response and occurrence of late response to peginterferon-alpha-2a one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2006; 44 (Suppl. 2): S23 (abstract 50).
16. ter Borg MJ, van Zonneveld M, Zeuzem S, et al,. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44: 721-727. (Pubitemid 44433729)
17. Yuen MF, Lai CL,. Combination therapy for chronic hepatitis B: simultaneous or sequential? Am J Gastroenterol 2007; 102 (1): 105-106.